Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.7828
−$0.0272 · -0.97%
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Regular session
$2.7828
−$0.0272 · -0.97%
Regular session · ET · Market data may be delayed.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $2.7828
52-week range
Current $2.7828
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
78
Undervalued
Sentiment
50
Mixed
Risk
42
Elevated Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $2.7828
52-week range
Current $2.7828
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 35.11M USD | 2.56M USD | — | — | — |
| Cost of goods sold | 6.26M USD | 797K USD | — | — | 1.89M USD |
| Gross profit | 28.86M USD | 1.76M USD | — | — | −1.89M USD |
| Research and development | 72.22M USD | 81.64M USD | 72.02M USD | 61.06M USD | 48.76M USD |
| Selling, general, and administrative | 43.52M USD | 61.52M USD | 35.51M USD | 27.02M USD | 24.7M USD |
| Operating expenses | 115.74M USD | 38.16M USD | 107.52M USD | 87.57M USD | 73.46M USD |
| Interest income | 4.58M USD | 5.77M USD | 4.58M USD | 219K USD | 10K USD |
| Interest expense | 8.88M USD | 8.77M USD | 5.78M USD | 3.99M USD | 3.64M USD |
| Depreciation and amortization | 1.28M USD | 796K USD | 419K USD | 513K USD | 1.89M USD |
| Operating income | −86.88M USD | −36.4M USD | −107.52M USD | −87.57M USD | −75.35M USD |
| Net income | −79.2M USD | −37.45M USD | −101.17M USD | −93.87M USD | −88.7M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.5M0.00%2.3T USD0.03%$379.14-0.50%
iShares Russell 2000 ETFIWM6.09M0.01%78.56B USD0.19%$277.1-0.22%
Vanguard Extended Market ETFVXF4.14M0.00%95.4B USD0.05%$232.87-0.27%
Vanguard Russell 2000 ETFVTWO1.88M0.01%18B USD0.06%$111.92-0.26%
iShares Micro-Cap ETFIWC745.86K0.06%1.33B USD0.60%$182.44-0.50%
ALPS Medical Breakthroughs ETFSBIO351.22K0.19%188.26M USD0.50%$53.835-0.54%
Vanguard Russell 2000 Value ETFVTWV302.56K0.02%1.4B USD0.06%$185.63+0.36%
Avantis U.S. Small Cap Equity ETFAVSC299.48K0.01%3.04B USD0.25%$69.84+0.30%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Value ETFVTWVAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
